New antibody IMP761 tested for safety in healthy volunteers
NCT ID NCT06637865
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether a new drug called IMP761 is safe and tolerable in 79 healthy adults aged 18-55. Participants receive either IMP761 or a placebo intravenously, along with a harmless immune challenge (KLH) to see how the drug affects immune responses. The study does not aim to treat any disease; it simply gathers safety data and measures how the drug behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMP761 (a LAG-3 agonist antibody)
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHDR
RECRUITINGLeiden, 2333, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••